CytomX Therapeutics Inc
NASDAQ:CTMX

Watchlist Manager
CytomX Therapeutics Inc Logo
CytomX Therapeutics Inc
NASDAQ:CTMX
Watchlist
Price: 2.5 USD 0.81% Market Closed
Market Cap: 393.9m USD

Relative Value

The Relative Value of one CTMX stock under the Base Case scenario is 0.29 USD. Compared to the current market price of 2.5 USD, CytomX Therapeutics Inc is Overvalued by 89%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CTMX Relative Value
Base Case
0.29 USD
Overvaluation 89%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
73
vs Industry
91
Median 3Y
2.8
Median 5Y
7.9
Industry
7.3
Forward
4.9
vs History
15
vs Industry
13
Median 3Y
-1.6
Median 5Y
-3.9
Industry
23.3
Forward
-11.5
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-4
Industry
19.8
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-3.9
Industry
22.6
vs History
17
vs Industry
Median 3Y
-3.3
Median 5Y
3.7
Industry
2.7
vs History
47
vs Industry
85
Median 3Y
0.7
Median 5Y
2
Industry
7.6
Forward
3.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.4
vs History
9
vs Industry
20
Median 3Y
0
Median 5Y
-0.9
Industry
4.7
Forward
16.2
vs History
11
vs Industry
17
Median 3Y
0
Median 5Y
-0.8
Industry
4.8
Forward
-66.1
vs History
vs Industry
25
Median 3Y
-0.7
Median 5Y
-1.1
Industry
5.3
vs History
vs Industry
21
Median 3Y
-0.7
Median 5Y
-1.1
Industry
3.8
vs History
15
vs Industry
71
Median 3Y
2.4
Median 5Y
3.5
Industry
5

Multiples Across Competitors

CTMX Competitors Multiples
CytomX Therapeutics Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
CytomX Therapeutics Inc
NASDAQ:CTMX
393.9m USD 2.7 9.5 8.3 8.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 706 744.2 -160 203.2 -194 537.7 -192 317.8
US
Abbvie Inc
NYSE:ABBV
334.3B USD 5.8 80.5 15.3 22.6
US
Amgen Inc
NASDAQ:AMGN
160.4B USD 4.7 27 14.5 23.9
US
Gilead Sciences Inc
NASDAQ:GILD
139.1B USD 4.8 23.3 10.1 14
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.1B USD 10.6 -119.4 25.4 26.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 090.1 -533.3 -580.7 -565.3
AU
CSL Ltd
ASX:CSL
117.5B AUD 5.1 28 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.2B USD 4.2 13.2 11.8 13.2
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.7 -66.6 -60.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
43.3B USD 18.4 -160.4 -720.3 -361
P/S Multiple
Revenue Growth P/S to Growth
US
CytomX Therapeutics Inc
NASDAQ:CTMX
Average P/S: 3 064 446.4
2.7
-49%
N/A
FR
Pharnext SCA
OTC:PNEXF
33 706 744.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.6
10%
1.1
US
E
Epizyme Inc
F:EPE
2 090.1
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
4%
1.1
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
18.4
29%
0.6
P/E Multiple
Earnings Growth PEG
US
CytomX Therapeutics Inc
NASDAQ:CTMX
Average P/E: 30.2
9.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 203.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.5
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
27
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.3
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -119.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.3 N/A N/A
AU
CSL Ltd
ASX:CSL
28
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -160.4 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
CytomX Therapeutics Inc
NASDAQ:CTMX
Average EV/EBITDA: 14.7
8.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 537.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.5
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -720.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
CytomX Therapeutics Inc
NASDAQ:CTMX
Average EV/EBIT: 18.7
8.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 317.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.6
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.9
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -361 N/A N/A